China National Drug Administration Approves Country’s First Immuno-Oncology Agent

09:32 EDT 15 Jun 2018 | Pharmaceutical Processing

News

The first and only PD-1 inhibitor approved in China opens a new era of Immuno-Oncology treatment for a type of lung cancer.

Contributed Author:

Bristol-Myers Squibb Company

Topics:

More From BioPortfolio on "China National Drug Administration Approves Country’s First Immuno-Oncology Agent"